Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482311 | 1.00 | KMT2A (0.61) | KMT2AADRB1PDCD1CD274HTR2C | |
| SCHEMBL5772537 | 1.00 | KMT2A (0.61) | KMT2AADRB1PDCD1CD274HTR2C | |
| Hydrochloric Acid SCHEMBL4876770 | 0.99 | KMT2A (0.60) | KMT2AADRB1PDCD1CD274HTR2C | |
| Hydrochloric Acid SCHEMBL4876659 | 0.99 | KMT2A (0.60) | KMT2AADRB1PDCD1CD274HTR2C | |
| Hydrochloric Acid SCHEMBL4876651 | 0.99 | KMT2A (0.60) | KMT2AADRB1PDCD1CD274HTR2C | |
| SCHEMBL5742585 | 0.91 | KMT2A (0.65) | KMT2AADRB1PDCD1CD274HTR2C | |
| Hydrochloric Acid SCHEMBL4880648 | 0.90 | KMT2A (0.63) | KMT2AADRB1PDCD1CD274HTR2C | |
| SCHEMBL5469094 | 0.88 | KMT2A (0.64) | KMT2APDCD1CD274ALDH1A1SLC6A4 | |
| SCHEMBL5475847 | 0.88 | KMT2A (0.75) | KMT2APDCD1CD274ALDH1A1SLC6A4 | |
| SCHEMBL5475853 | 0.88 | KMT2A (0.75) | KMT2APDCD1CD274ALDH1A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KMT2A 1301/4885ADRB1 164/4885PDCD1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.